Johnson & Johnson Patent-Cliff Exposure & CMS Drug Spending Portfolio

Johnson & Johnson (New Brunswick, NJ): 57 reconciled FDA prescription therapies (9.1% 2025 to 2030 cliff risk), $25.58B 2024 CMS Part D & Medicaid spend, and 124 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNew Brunswick, NJ
Reconciled FDA Portfolio Therapies57
2025 to 2030 Patent-Cliff Revenue Exposure9.1%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$25.58B
2024 Medicare Part D Spend$18.44B
2024 Medicaid Spend$7.15B
California HCAI SB 17 Filings124 WAC filings (max 26.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.